TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of “Buy” from Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have received an average rating of “Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $174.30.

Several equities analysts have recently commented on TMDX shares. Oppenheimer boosted their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Robert W. Baird started coverage on TransMedics Group in a report on Tuesday, September 24th. They issued an “outperform” rating and a $200.00 target price on the stock. Needham & Company LLC initiated coverage on TransMedics Group in a research report on Wednesday, August 21st. They set a “buy” rating and a $208.00 price objective for the company. Morgan Stanley lifted their target price on TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Finally, Stephens increased their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd.

TransMedics Group Price Performance

TransMedics Group stock opened at $137.18 on Thursday. The firm has a market cap of $4.58 billion, a PE ratio of -403.47 and a beta of 1.99. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The stock’s fifty day moving average price is $155.91 and its two-hundred day moving average price is $135.44. TransMedics Group has a one year low of $36.42 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. TransMedics Group’s revenue was up 117.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.03) earnings per share. As a group, research analysts expect that TransMedics Group will post 1.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the transaction, the insider now owns 20,843 shares in the company, valued at approximately $3,089,766.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Anil P. Ranganath sold 4,289 shares of TransMedics Group stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total value of $652,785.80. Following the completion of the transaction, the insider now directly owns 8,893 shares in the company, valued at approximately $1,353,514.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,205 shares of company stock valued at $10,089,374 in the last ninety days. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors have recently modified their holdings of TMDX. Wasatch Advisors LP acquired a new position in TransMedics Group in the first quarter valued at $32,162,000. Vaughan Nelson Investment Management L.P. acquired a new position in shares of TransMedics Group during the second quarter valued at about $39,862,000. Driehaus Capital Management LLC raised its stake in TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after buying an additional 202,867 shares during the period. First Light Asset Management LLC boosted its holdings in TransMedics Group by 22.0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock worth $59,538,000 after acquiring an additional 136,217 shares in the last quarter. Finally, Hood River Capital Management LLC acquired a new stake in TransMedics Group in the second quarter valued at approximately $18,854,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.